Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28318850 | 1.00 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP | |
| Hydrochloric Acid SCHEMBL30461880 | 0.98 | SLC7A5 (0.46) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL9172559 | 0.87 | SLC7A5 (0.55) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL14780592 | 0.80 | HSD17B10 (0.49) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL2921395 | 0.80 | PRSS1 (0.47) | MAPTALDH1A1KMT2AKDM4ERECQL | |
| SCHEMBL1848010 | 0.79 | DAO (0.39) | ALDH1A1KMT2ATDP1POLBTHRB | |
| SCHEMBL15390388 | 0.79 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL11559690 | 0.79 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL4249863 | 0.79 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL4249865 | 0.79 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20110263601-A1 | METHODS OF TREATING ULCERATIVE COLITIS | LEXICON PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20100317664-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-0581250-B1 | Process for biotechnical preparation of L-thienylalanines in enantiomere pure form from 2-hydroxy-3-thienyl-acrylic acids and their use | HOECHST AG (DE) | 1999-03-03 | — | — | EP | disclosed |
| US-5780640-A | Process for the biotechnological preparation of L-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acids and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| US-5688672-A | Process for the biotechnological preparation of L-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-18 | — | — | US | disclosed |
| US-5480786-A | Process for the biotechnological preparation of l-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acids, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-02 | — | — | US | disclosed |
| EP-0581250-A2 | Process for biotechnical preparation of L-thienylalanines in enantiomere pure form from 2-hydroxy-3-thienyl-acrylic acids and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0005647-B1 | HYDANTOIN COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | Lilly Industries Limited (GB) | 1982-06-09 | — | — | EP | disclosed |
| US-4293563-A | ANTIASTHMATICS | LILLY INDUSTRIES LIMITED (GB) | 1981-10-06 | — | — | US | disclosed |
| US-4241073-A | ASTHMA | LILLY INDUSTRIES LIMITED (GB) | 1980-12-23 | — | — | US | disclosed |
| EP-0005647-A1 | Hydantoin compounds, their preparation and pharmaceutical formulations containing them | Lilly Industries Limited (GB) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | SLC7A5 1902/4885PKM 1328/4885PTGS1 7/4885 |
| US-20110263601-A1 | METHODS OF TREATING ULCERATIVE COLITIS | TPH2, TPH1, HNMT | SLC7A5 2776/4885PKM 2653/4885PTGS1 55/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | SLC7A5 1017/4885PKM 2587/4885PTGS1 276/4885 |
| US-20100317664-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, SLC10A2 | SLC7A5 213/4885PKM 1644/4885PTGS1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.